Fertility Concerns a Significant Issue for Gynecologic Cancer Survivors

July 29, 2022 12:59 pm

by Jessica Nye, PhD

A systematic review found that fertility and parenthood were important and affected quality of life for young patients with gynecologic cancers; however, counseling and referral to fertility services is suboptimal. These findings were published in The Read more

Understanding the genetic testing-related information needs of ovarian cancer patients

July 29, 2022 11:45 am

Reviewed by Emily Henderson, B.Sc.

JMIR Publications recently published “Understanding the Information Needs of Patients With Ovarian Cancer Regarding Genetic Testing to Inform Intervention Design: Interview Study” in JMIR Cancer, which reported that experts in gynecological cancer care recommend that … Read more

Meta-Analysis Examines Link Between Aspirin Use and Ovarian Cancer Risk

July 28, 2022 10:32 am

by The ASCO Post Staff

Frequent aspirin use may be linked with lower ovarian cancer risk in individuals with multiple risk factors, according to a new study published by Hurwitz et al in the Journal of Clinical Oncology.

“Ovarian … Read more

Cure Rate After Chemotherapy in Stage III Ovarian Cancer

July 27, 2022 11:09 am

by Vicki Moore, PhD

Researchers found that 18% of patients with advanced ovarian cancer remained disease-free for at least 10 years after receiving chemotherapy and were likely cured. The team detailed their findings in Gynecologic Oncology.

To determine what … Read more

ADCs Begin to Carve a Place in the Treatment Landscape for Ovarian Cancer

July 26, 2022 2:39 pm

by Brittany Lovely

Patients with recurrent, platinum-resistant ovarian cancer have limited effective treatment options available, but a class of targeted antibody-drug conjugates (ADCs) represent a promising development for this population.1

The treatment landscape for patients who experience disease progression

Read more

Vitamin D therapy may be a useful addition to the treatment of ovarian cancer, study suggests

July 26, 2022 12:35 pm

by Emily Henderson, B.Sc.

Ovarian cancer has one of the highest death rates of all cancers. One reason for this is that cancer turns the body’s defenses against itself. However, new research from Nagoya University published in Matrix Biology suggests … Read more

Epigenetic ‘Priming’ Boosts Cancer Immunotherapy

July 25, 2022 11:11 am

by Will Doss

An epigenetic inhibitor can boost immune system activity in patients with ovarian cancer, making them more suitable for treatment with immunotherapy, according to a Northwestern Medicine study published in the Journal of Clinical Investigation.

This could … Read more

ASCO, ACCC Issue Recommendations to Boost Clinical Trial Diversity

July 24, 2022 10:44 am

by Jason Harris

The American Society of Clinical Oncology (ASCO) and the Association of Community Cancer Centers (ACCC) have issued a joint statement outlining 6 recommendations for boosting participation among underserved communities.1

Increasing the racial and ethnic diversity in

Read more

Ofranergene Obadenovec/Paclitaxel Combo Misses Survival End Points in Platinum-Resistant Ovarian Cancer

July 20, 2022 12:09 pm

by Caroline Seymour

The combination of ofranergene obadenovec and paclitaxel failed to elicit a statistically significant improvement in progression-free survival or overall survival compared with paclitaxel alone in patients with platinum-resistant ovarian cancer, missing the coprimary end points of the Read more

Researchers test drug combination as means to prevent drug resistance in cancer cells

July 14, 2022 11:24 am

by Leslie Cantu

Michael Lilly, M.D., left, and Joe Delaney, Ph.D., are teaming up for a clinical trial to bring Delaney’s lab research into the patient realm. Photo by Kristin Lee

A combination of up to five drugs normally used … Read more

Effects of Food Insecurity Interventions on Cancer Treatment Adherence, Completion

July 13, 2022 11:22 am

by Vicki Moore, PhD

A recent study evaluated the effects programs aimed at addressing food insecurity have on treatment outcomes for patients with cancer. Each intervention seemed beneficial, with a voucher-plus-pantry program appearing to be the most effective. The study’s … Read more

Breast, Ovarian Cancer Study Finds Ties Between Types of BRCA Alterations, Treatment Response

July 7, 2022 10:30 am

NEW YORK – Epigenetic changes to the promoter regions of BRCA1 appear to have a different effect on treatment response than genomic alterations in BRCA1 or BRCA2 in triple-negative breast cancer (TNBC) or ovarian carcinoma patients, new research suggests.

For Read more

FDA Approves Tafinlar Plus Mekinist for Patients With BRAF V600-Mutant Solid Cancers

June 23, 2022 10:56 am

by Brielle Benyon

Tafinlar plus Mekinist is now approved by the Food and Drug Administration to treat adults and children over the age of 6 who have BRAF V600-mutant advanced solid cancers.

The Food and Drug Administration (FDA) approved Tafinlar

Read more

Farletuzumab Ecteribulin Shows Early Activity in Platinum-Resistant Ovarian Cancer

June 21, 2022 11:03 am

by Chris Ryan

The antibody-drug conjugate farletuzumab ecteribulin demonstrated notable antitumor activity with a manageable safety profile in patients with platinum-resistant ovarian cancer.

The antibody-drug conjugate (ADC) farletuzumab ecteribulin (MORab-202) demonstrated notable antitumor activity with a manageable safety profile in

Read more

Examining factors that may impact ovarian cancer survival disparities

June 20, 2022 10:33 am

by Coco Davis/ Fred Hutchinson Cancer Research Center

Epithelial ovarian cancer (EOC) is the most lethal gynecologic malignancy among women in the United States (US). Although the incidence rate is higher among White women, Black women have the lower survival … Read more

Tool improves women’s ‘sense of control’ over ovarian cancer symptoms

June 18, 2022 12:08 pm

by Jennifer Byrne

Women with recurrent ovarian cancer experience an average of 14 disease or treatment-related symptoms at any given time over the course of their disease.

“It’s a huge symptom burden,” Heidi Donovan, PhD, RN, professor of health and … Read more

Neoadjuvant Abemaciclib and Fulvestrant Facilitates High Complete Gross Resection Rate in Low-Grade Serous Cancer

June 15, 2022 12:04 pm

by Caroline Seymour

The combination of abemaciclib and fulvestrant led to encouraging responses when used as neoadjuvant therapy which translated to high complete gross resection rates in patients with advanced, low-grade serous ovarian, fallopian tube, and peritoneal carcinoma.

The combination

Read more

Real-World Data Identify Significant Differences in Tolerability Among Approved PARP Inhibitors in Ovarian Cancer

June 14, 2022 11:57 am

by Lindsey Fischer

A real-world analysis showed that the proportion of women with ovarian cancer who required dose modifications or treatment discontinuations while receiving PARP inhibitors differed significantly between olaparib, niraparib, and rucaparib.

Patients with ovarian cancer treated with FDA-approved

Read more

Ovarian cancer survivors have shown resilience in the face of the pandemic, but are still at risk for mental health challenges

June 8, 2022 5:08 pm

by University of Chicago Medical Center

Clearity offers psychosocial support through our Steps Through OC program for patients, survivors and caregivers. If you would like personal one-to-one assistance with the stress and challenges associated with an ovarian cancer diagnosis, our

Read more